
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is a global biotechnology company with a strong portfolio of therapies for infectious diseases such as HIV and hepatitis B and C. The recent acquisition of Pharmasset has brought a potential blockbuster drug for hepatitis C, enhancing Gilead's position in the market. In the near term, the company's success will depend on the adoption and growth of its HIV therapies, while longer term, its pipeline in cell therapy and oncology could drive further growth. The company is also focused on sustainability and diversity, which could help enhance its reputation and attract talent.
Bears say
Gilead Sciences is facing potential surprise competition for its HIV PrEP franchise with the FDA acceptance of 300 mg QW oral Yeztugo. Additionally, its pipeline may face challenges from emerging oral competitors and clinical trial risks. Furthermore, Gilead may be impacted by macroeconomic factors due to COVID-19. Despite having strong leadership in the HIV market, the company may experience pricing pressure in the future, and its oncology assets may face commercial and scientific complexities. Gilead's commitment to transparency and strong governance practices may provide some reassurance, but it remains to be seen how the company will navigate these challenges and maintain positive cash flows.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares